Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v13.i4.10
pages 265-282

Methylation-Based Biomarkers for Early Detection of Urological Cancer

Rui Manuel Ferreira Henrique
Department of Pathology, Portuguese Oncology Institute—Porto; and Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Sa-lazar (ICBAS), University of Porto, Portugal
Vera L. Costa
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Sa-lazar (ICBAS), University of Porto, Portugal
Carmen Jeronimo
Cancer Biology & Epigenetics Group, Research Center, Portuguese Oncology Institute-Porto (Cl-IPO-Porto), Rua Dr. Antonio Bernardino Almeida, 4200-072, Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences


Genitourinary (prostate, bladder, and kidney) cancers together comprise the most common type of human neoplasms. As a common feature to these types of malignancy, the disease is frequently asymptomatic at its earlier stages, when curative treatment is most likely to be successful. Moreover, available tests for genitourinary cancer screening (mostly directed to prostate cancer) are characterized by variable (usually low) sensitivity and specificity, preventing a consensual support for their routine use by the medical community. Thus, the timely and accurate detection of GU cancer remains a significant clinical challenge. Over the last decade, a new generation of cancer biomarkers, based on the characterization of the methylome, has emerged and has showed promise in the detection of several common malignant tumors. The investigation of novel genitourinary cancer methylation-based markers constitutes an attractive and fast-growing research field, and several studies reported on the feasibility of examining these markers in body fluids (urine and blood) for early, noninvasive cancer detection. Importantly, the use of quantitative, high-throughput techniques enables relatively easy and reproducible detection of hypermethylation at multiple gene loci in a single test, thus facilitating its translation to the clinics. Although available data is still insufficient to support the clinical implementation of these markers at the present time, further developments in methylation analysis are likely to provide valuable tests for genitourinary cancer screening and management.

Articles with similar content:

Dysregulated Expression of Long Noncoding RNAs in Endometriosis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 2
Lian-wen Zheng, Li-ting Sun, Dan-dan Li, Lu-lu Fu, Xue-ying Zhang, Ying Xu, Man-hua Cui, Xu Zhou, Di Zhang, Chun-jin Li
Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 2
Lian-wen Zheng, Dan-dan Li, Lu-lu Fu, Feng-ge Wang, Ying Xu, Xue-ying Zhang, Xu Zhou, Ling-yun Li, Shu-xiong Chen, Chun-jin Li
The Role of HSP70 in the Diagnosis of HCC
Onco Therapeutics, Vol.5, 2014, issue 3-4
Gabriele Multhoff, Lydia Giannitrapani
Genomic Pathology and Cancer Biomarkers: Prostate Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Kenneth A. Iczkowski
SNPs in MicroRNA Binding Sites as Prognostic and Predictive Cancer Biomarkers
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Joanne B. Weidhaas, Carina Preskill